Johnson & Johnson to buy Shockwave Medical for $13.1 billion

Johnson & Johnson on Friday announced it would acquire heart device firm Shockwave Medical for $13.1 billion. It’s J&J’s second billion-dollar deal in the cardiovascular space in two years, following its 2022 purchase of Abiomed for $16.6 billion.

The company also said in November that it would buy private heart device company Laminar for $400 million.

Shockwave Medical’s device works to break down calcified plaque in the coronary and peripheral arteries using sonic pressure waves — a treatment called intravascular lithotripsy. The founders based the technology on lithotripsy to remove kidney stones, a therapy that has been in use since the 1980s. According to a press statement, Shockwave has treated 400,000 patients with this method globally. The company earned its first clearance from the Food and Drug Administration in 2016, and went public in 2019 at a share price of $17. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In